News | November 01, 2024
Supriya Lifescience reports 19% revenue increase in Q2 FY25
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Akums Drugs will undertake this development and commercialization in India
Subscribe To Our Newsletter & Stay Updated
